A Phase 1 interventional study of Icatibant (30 mg) in Hereditary Angioedema (HAE), sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 7th largest by enrollment, is the only one that started in 2014, is the only one in phase 1, and was the 7th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2014.
This study's enrollment of 12 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 26 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 27th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2014, is one of 5 in phase 1, and was the 25th registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
Icatibant has been studied for the treatment of acute attacks of hereditary angioedema (HAE), an autosomal dominant disorder characterized by recurrent and self-limiting episodes of edema of the skin, larynx, and gastrointestinal tract. The most serious manifestation of an HAE attack is laryngeal edema, causing obstruction of the upper airways that may lead to death by asphyxiation if undiagnosed and/or untreated.
Icatibant has been approved in over 40 countries around the world including the United States (US) and Europe for the treatment of acute attacks of hereditary angioedema (HAE) in adults. This study is being conducted to evaluate the safety and tolerability of icatibant in a Japanese population and to evaluate whether race/ethnicity impacts the pharmacokinetics of icatibant after single subcutaneous injection.
This is an open-label, single-arm study that will enroll at least 12 Japanese subjects (in order to have 12 subjects complete the study), age 18-55 years inclusive. All subjects will receive a single subcutaneous injection of 30mg icatibant. The study will be conducted at 1 site in the US. The study will consist of a Screening Period, a Treatment Period, and a Follow-Up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
Drug: Icatibant (30 mg)
On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
Also known as: Firazyr
Peak Plasma Concentration (Cmax) of Icatibant and Metabolites
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.
Time frame: Over 48 hours post-dose
Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
Time frame: Over 48 hours post-dose
Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites
The time it takes for the blood plasma concentration of a substance to halve.
Time frame: Over 48 hours post-dose
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites
AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Time frame: Over 48 hours post-dose
Total Body Clearance (CL/F) of Icatibant
The rate at which a drug is removed from the body.
Time frame: Over 48 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites
AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Time frame: Over 48 hours post-dose
The Total Number of Treatment-Emergent Adverse Events
Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.
Time frame: TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration
The Percentage of Subjects With Any Injection Site Reactions.
Time frame: Over 48 hours post-dose
Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results
Time frame: Over 48 hours post-dose
Change From Baseline in Diastolic Blood Pressure
Time frame: Over 48 hours post-dose
Change From Baseline in Systolic Blood Pressure
Time frame: Over 48 hours post-dose
Change From Baseline in Pulse Rate
Time frame: Over 48 hours post-dose
| Milestone | Icatibant (30 mg) |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.
| ng/mL | Icatibant (30 mg) |
|---|---|
| Icatibant | 1190 ± 261 |
| Metabolite 1 | 340 ± 67.7 |
| Metabolite 2 | 365 ± 74.8 |
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
| hr | Icatibant (30 mg) |
|---|---|
| Icatibant | 0.67 ± 0.20 |
| Metabolite 1 | 1.92 ± 0.289 |
| Metabolite 2 | 1.92 ± 0.289 |
The time it takes for the blood plasma concentration of a substance to halve.
| hr | Icatibant (30 mg) |
|---|---|
| Icatibant | 1.77 ± 0.356 |
| Metabolite 1 | 3.69 ± 0.579 |
| Metabolite 2 | 4.11 ± 1.01 |
AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
| ng*hr/mL | Icatibant (30 mg) |
|---|---|
| Icatibant | 2320 ± 403 |
| Metabolite 1 | 1750 ± 308 |
| Metabolite 2 | 1960 ± 346 |
The rate at which a drug is removed from the body.
| mL/hr | Icatibant (30 mg) |
|---|---|
| Total Body Clearance (CL/F) of Icatibant | 13200 ± 1890 |
Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.
| Treatment Emergent Adverse Events | Icatibant (30 mg) |
|---|---|
| The Total Number of Treatment-Emergent Adverse Events | 2 |
| percentage of participants | Icatibant (30 mg) |
|---|---|
| Erythema | 100.00 |
| Warm sensation | 50.00 |
| Swelling | 91.67 |
| Cutaneous pain | 33.33 |
| Itching/Pruritus | 8.33 |
| Burning sensation | 8.33 |
| percentage of participants | Icatibant (30 mg) |
|---|---|
| Screening | 91.67 |
| Day 1, Pre-dose | 50.00 |
| Baseline | 50.00 |
| Day 1, 0.75 hours | 33.33 |
| Day 1, 8 hours | 33.33 |
| Day 2, 24 hours | 66.67 |
| Day 3, 48 hours | 66.67 |
AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
| ng*hr/mL | Icatibant (30 mg) |
|---|---|
| Icatibant | 2320 ± 402 |
| Metabolite 1 | 1740 ± 307 |
| Metabolite 2 | 1950 ± 345 |
| mmHg | Icatibant (30 mg) |
|---|---|
| Day 1, 0.5 h | -2.0 ± 6.42 |
| Day 1, 1 h | -3.8 ± 4.30 |
| Day 1, 2 h | -5.2 ± 4.57 |
| Day 1, 4 h | -5.2 ± 7.52 |
| Day 1, 6 h | -4.8 ± 8.07 |
| Day 1, 8 h | -4.5 ± 6.67 |
| Day 1, 12 h | -3.4 ± 9.06 |
| Day 2, 24 h | -1.8 ± 7.76 |
| Day 3, 48 h | -5.3 ± 6.18 |
| mmHg | Icatibant (30 mg) |
|---|---|
| Day 1, 0.5 h | -1.8 ± 12.07 |
| Day 1, 1 h | -1.9 ± 13.03 |
| Day 1, 2 h | -5.8 ± 14.21 |
| Day 1, 4 h | -7.3 ± 17.06 |
| Day 1, 6 h | -4.3 ± 16.20 |
| Day 1, 8 h | -3.0 ± 11.52 |
| Day 1, 12 h | -4.4 ± 14.11 |
| Day 2, 24 h | -6.2 ± 11.98 |
| Day 3, 48 h | -6.4 ± 12.72 |
| beats per minute | Icatibant (30 mg) |
|---|---|
| Day 1, 0.5 h | 1.4 ± 7.53 |
| Day 1, 1 h | 0.1 ± 5.38 |
| Day 1, 2 h | -3.0 ± 9.67 |
| Day 1, 4 h | -6.3 ± 9.91 |
| Day 1, 6 h | -0.1 ± 11.15 |
| Day 1, 8 h | -3.6 ± 10.88 |
| Day 1, 12 h | -3.2 ± 10.50 |
| Day 2, 24 h | -6.8 ± 9.02 |
| Day 3, 48 h | -4.0 ± 9.77 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Icatibant (30 mg) | — | 0/12 (0%) | 2/12 (16.7%) |
| Event | Icatibant (30 mg) |
|---|---|
| CostochondritisMusculoskeletal and connective tissue disorders | 1/12 |
| Injection Site PainGeneral disorders | 1/12 |
The Safety Set consisted of all subjects who had taken the single dose of icatibant.
| Age, Categorical(Participants) | Icatibant (30 mg) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 12 |
| >=65 years | 0 |
| Age, Continuous(years) | Icatibant (30 mg) |
|---|---|
| Mean | 30.7 ± 8.08 |
| Sex: Female, Male(Participants) | Icatibant (30 mg) |
|---|---|
| Female | 6 |
| Male | 6 |
| Region of Enrollment(Participants) | Icatibant (30 mg) |
|---|---|
| United States | 12 |
Ran from Feb 2014 to primary completion in Feb 2014, 0 months.
Results were first posted in Jan 2015, 10 months after primary completion.
Of 13 phase 1 interventional studies under Angioedemas, Hereditary, half reached primary completion within 5 months of starting (the median); a quarter within 4 and three quarters within 9. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icatibant